News
Orserdu Approved for ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
In patients whose tumors had ESR1 mutations, elacestrant reduced the risk of progression or death by 45%.
Regular users may be at risk for serous retinal detachment, retinal vascular occlusion, and ischemic optic neuropathy